We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
5-Amino-1MQ is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most 5-Amino-1MQ studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2014–2025.
Based on 7 studies
Confidence
LowBy outcome
The current evidence for 5-Amino-1MQ is insufficient to assign an evidence score, based on 7 indexed studies. A grey-market research chemical with NO human trials of any kind — every result below is from mice or cells. 5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), not a peptide (it's grouped here with research peptides by category convention). In diet-induced-obese mice, an NNMT inhibitor limited fat-mass gain and improved glucose tolerance — a genuinely interesting preclinical signal. But it has never been tested in a single human, it is not an approved drug or a regulated dietary supplement, and it is sold online with no quality control. Its long-term safety and its effects on human NAD+/methylation metabolism are completely unknown. This entry exists to inform, not to recommend. Representative study: PMID 24717514.
The commonly studied dose of 5-Amino-1MQ is No legitimate or recommended dose — 5-amino-1MQ is an unapproved grey-market research chemical with no human dosing data and no quality control. We do NOT provide a dosing protocol. The only published dosing is in mice (once-daily for 28 days in diet-induced-obese animals), which does not translate to a human dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
5-Amino-1-methylquinolinium (5A1MQ)
A grey-market research chemical with NO human trials of any kind — every result below is from mice or cells. 5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), not a peptide (it's grouped here with research peptides by category convention). In diet-induced-obese mice, an NNMT inhibitor limited fat-mass gain and improved glucose tolerance — a genuinely interesting preclinical signal. But it has never been tested in a single human, it is not an approved drug or a regulated dietary supplement, and it is sold online with no quality control. Its long-term safety and its effects on human NAD+/methylation metabolism are completely unknown. This entry exists to inform, not to recommend.
An intriguing preclinical NNMT-inhibitor story with consistent fat-loss and glucose benefits in obese mice, but zero human trials of any kind — no safety, no pharmacokinetics, nothing.
5-Amino-1MQ (5-amino-1-methylquinolinium, '5A1MQ') is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — despite being grouped here with research peptides, it is a synthetic small molecule, not a peptide.
NNMT is a cytosolic enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNAM) and S-adenosylhomocysteine.
Because nicotinamide is a precursor of NAD+ and SAM is the cell's universal methyl donor, NNMT sits at the intersection of NAD+ metabolism, one-carbon/methylation balance, and polyamine flux.
The therapeutic hypothesis comes from mouse genetics: a 2014 Nature paper (Kraus et al.) showed that knocking down Nnmt in white adipose tissue and liver protected mice from diet-induced obesity by raising cellular energy expenditure, increasing tissue SAM and NAD+, and driving polyamine flux.
That made NNMT an attractive pharmacological target, and 5-amino-1MQ is one of the chemical-probe NNMT inhibitors used to test the idea in vivo.
The most directly relevant study (Babula et al., 2024, Diabetes Obes Metab) dosed diet-induced-obese (DIO) mice with 5A1MQ once daily for 28 days and reported dose-dependent reductions in body-weight and fat-mass gain, improved oral glucose tolerance and insulin sensitivity, lower hyperinsulinaemia, and attenuated hepatic steatosis — alongside a pharmacokinetic profile showing systemic exposure and distribution to adipose, muscle, and liver.
A related study combined 5-amino-1-methylquinolinium with a low-fat-diet switch and saw dramatic adiposity/weight loss in DIO mice plus a distinct gut microbiome. Other NNMT-inhibitor chemotypes (e.g.
JBSNF-000028, AMO-NAM) reproduce metabolic and cardiac benefits in mouse models, and reviews frame NNMT as a candidate target for metabolic syndrome. Here is the honest, load-bearing caveat: ALL of this is preclinical.
There has never been a published human trial of 5-amino-1MQ — not a phase-I safety study, not a pharmacokinetic study, nothing.
It is not approved by any regulator, it is not a lawful dietary-supplement ingredient, and the material sold online is an unregulated grey-market research chemical with no guarantee of identity, purity, or sterility.
Manipulating NNMT activity also perturbs NAD+ and cellular methylation — pathways whose long-term modulation in humans is unstudied, and where unintended effects (on methylation-dependent gene regulation, polyamine balance, or downstream metabolism) cannot be ruled out.
The evidence here is therefore UNSCORED: an intriguing mouse-and-cell story with zero human data, sandboxed out of all goal- and stack-based recommendations.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using SAM to form 1-methylnicotinamide. Inhibiting it is proposed to spare nicotinamide (a NAD+ precursor) and SAM. Demonstrated only in cell and mouse systems — never measured in humans.
In mice, NNMT knockdown raised adipose SAM and NAD+ levels, increased polyamine flux, and augmented cellular energy expenditure. This is the proposed route from enzyme inhibition to a leaner metabolic phenotype — established in rodent models, with no human confirmation.
By raising energy expenditure in white adipose tissue and liver, NNMT inhibition limited diet-induced fat-mass gain and improved insulin sensitivity in obese mice. Whether any of this translates to humans is entirely unknown — there are no human data.
How 5-Amino-1MQ works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No legitimate or recommended dose — 5-amino-1MQ is an unapproved grey-market research chemical with no human dosing data and no quality control. We do NOT provide a dosing protocol. The only published dosing is in mice (once-daily for 28 days in diet-induced-obese animals), which does not translate to a human dose.
Can be taken without food
| Form | Type |
|---|---|
| 💊None — unapproved grey-market research chemical | Recommended |
There is no legitimate pharmaceutical form. 5-Amino-1MQ is a chemical-probe NNMT inhibitor used in mouse and cell research; it is not a medicine or a dietary supplement.
Minimum: 1 weeks
Optimal: 1 weeks
Cycling: Not required
Note: No approved or validated timing — the compound has never been tested in humans. This library does not endorse or schedule its use.
Dose-response data unavailable. The current published research for 5-Amino-1MQ does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
There has never been a published human trial of 5-amino-1MQ — no safety study, no pharmacokinetics, nothing. Every effect listed here is from mice or cells and may not translate to people.
In diet-induced-obese mice, an NNMT inhibitor dose-dependently limited body-weight and fat-mass gain. A genuine preclinical signal — not demonstrated in humans.
Obese mice showed improved oral glucose tolerance, better insulin sensitivity, and reduced hyperinsulinaemia. Mouse-only finding.
Liver histology in treated obese mice showed reduced fatty-liver pathology and normalized liver enzymes. Mouse-only finding.
Effects on human NAD+ metabolism, cellular methylation, and polyamine balance are unstudied. Long-term safety is completely unknown because no human has ever been studied.
Avoid — there are no human trials, no approved use, and no quality-controlled product. The mouse evidence does not justify human self-experimentation.
Avoid — interactions on the NAD+/methylation axis are unstudied and unpredictable.
Avoid entirely — completely unstudied.
5-Amino-1MQ acts on the NNMT/NAD+/methylation axis. Combining it with NAD+ precursors (NR, NMN, niacin, nicotinamide) has never been studied in humans; metabolic interactions are theoretically plausible and unpredictable.
There are no human drug-interaction data of any kind. Effects on methylation-dependent metabolism are unknown, so interactions cannot be predicted.
Tip: No human has ever been studied — the side-effect profile in people is genuinely unknown. This is itself the warning.
Tip: NNMT inhibition perturbs cellular methylation and NAD+ balance; long-term human consequences are unstudied.
Tip: Grey-market material has no identity/purity/sterility guarantees; contaminants are possible.
Timing is flexible for 5-Amino-1MQ — consistent daily use matters more than the time of day. There is no validated human dosing schedule because the compound has never been tested in humans.
5-Amino-1MQ should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are unknown human side-effect profile, unknown effects on NAD+/methylation/polyamine metabolism, harm from an unregulated, impure product. Use caution if any of these apply to you: Not an approved medicine and not a regulated dietary supplement — unapproved grey-market research chemical; do not self-source; No human safety data exists — every safety conclusion would be an extrapolation from mice; Pregnancy and breastfeeding (entirely unstudied).
Gonadorelin
Mostly mechanism / observationalA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.